Structure-activity relationship studies on a series of novel, substituted 1-benzyl-5-phenyltetrazole P2X7 antagonists

Journal of Medicinal Chemistry

Volumn 49, Issue 12, 2006, Pages 3659-3666

  Nelson, Derek W ^a   Gregg, Robert J ^a   Kort, Michael E ^a   Perez Medrano, Arturo ^a   Voight, Eric A ^a   Wang, Ying ^a   Grayson, George ^a   Namovic, Marian T ^a   Donnelly Roberts, Diana L ^a   Niforatos, Wende ^a   Honore, Prisca ^a   Jarvis, Michael F ^a   Faltynek, Connie R ^a   Carroll, William A ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 BENZYL 5 PHENYLTETRAZOLE DERIVATIVE; 3 [5 (2,3 DICHLOROPHENYL)TETRAZOL 1 YLMETHYL]PYRIDINE; INTERLEUKIN 1BETA; PURINE P2X7 RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; TETRAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ALLODYNIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIUM TRANSPORT; CONTROLLED STUDY; DOSE RESPONSE; DRUG DETERMINATION; DRUG EFFICACY; DRUG STRUCTURE; FLUOROMETRY; HUMAN; MOTOR COORDINATION; NEUROPATHIC PAIN; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ANALGESICS; ANIMALS; CELL LINE; HUMANS; INTERLEUKIN-1; LIGATION; MOTOR ACTIVITY; PAIN; PATCH-CLAMP TECHNIQUES; PERIPHERAL NERVOUS SYSTEM DISEASES; PHYSICAL STIMULATION; PYRIDINES; RATS; RECEPTORS, PURINERGIC P2; SPINAL NERVES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAZOLES; TOUCH;

EID: 33745142545     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm051202e     Document Type: Article

References (51)

1. North, R. A.; Barnard, E. A. Nucleotid receptors. Curr. Opin. Neurobiol. 1997, 7, 346-357.
2. Ralevic, V.; Burnstock, G. Receptors for purines and pyrimidines. Pharmacol. Rev. 1998, 50, 413-492.
3. Jacobsen, K. A.; Jarvis, M. F.; Williams, M. Purine and pyrimidine (P2) receptors as drug targets. J. Med. Chem. 2002, 45, 4057-4093.
4. North, R. A. Molecular physiology of P2X receptors. Physiol. Rev. 2002, 82, 1013-1067.
5. Burnstock, G.; King, B. F. Numbering of cloned P2 receptors. Drug Dev. Res. 1996, 38, 67-71.
6. Surprenant A.; Rassendren, F.; Kawashima, E.; North, R. A.; Buell, G. The cytolytic P2Z receptor for extracellular ATP identified as a P2X (P2X7) receptor. Science 1996, 272, 735-738.
7. El-Moatassim, C.; Dubyak, G. R. A novel pathway for the activation of phospholipase D by P2Z purinergic receptors in BAC1.2F5 macrophages. J Biol. Chem. 1992, 267, 23664-23673.
8. Falzoni, S.; Munerati, M.; Ferrari, D.; Spisani, S.; Moretti, S.; Di Virgilio, F. The purinergic P2Z receptor of human macrophage cells. Characterization and possible physiological roles. J. Clin. Invest. 1995, 95, 1207-1216.
9. 7. J. Biol Chem. 1997, 272, 5482-6486.
10. Ferrari, D.; Villalba, M.; Chiozzi, P.; Falzoni, S.; Ricciardi- Castagnoli, P.; DiVirgilio, F. Mouse microglia cells express a plasma membrane pore gated by extracellular ATP. J. Immunol. 1996, 156, 1531-1539.
11. (a) Irnich, D.; Burgstahler, R. Grafe, P. P2 nucleotide receptors in peripheral nerve trunk. Drug Dev. Res. 2001,52, 83-88.
12. 7) receptors regulate intracellular calcium and purine release. Neuroreport 1996, 7, 2533-2537.
13. (a) Deuchars, S. A.; Atkinson, L.; Brooke, R. E.; Musa, H.; Milligan, C. J.Batten, T. F. C.; Buckley, N. J.; Parson, S. H.; Deuchars, J. Neuronal P2 × 7 receptors are targeted to presynaptic terminals in the central and peripheral nervous system. J. Neurosci. 2001, 21, 7143-7152.
14. 7 Receptor Expression in Rodent Brain. J. Neurosci. 2004, 24, 6307-6314.
15. Buisman, H. P.; Steinberg, T. H.; Fischbarg, J.; Silverstein, S. C.; Vogelzang, S. A.; Ince, C.; Ypey, D. L.; Leijh, P. C. Extracellular ATP induces a large nonselective conductance in macrophage plasma membranes. Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 7988-7992.
16. + release. Am. J. Cell Physiol. 2004, 286, C1100-C1108.
17. Perregaux, D.; Gabel, C. A. Interleukin-1 β maturation and release in response to ATP and nigericin. Evidence that potassium depletion mediated by these agents is a necessary and common feature of their activity. J. Biol. Chem. 1994, 269, 15195-15203.
18. Walev, I.; Klein, J.; Husmann, M.; Valeva, A.; Strauch, S.; Wittz, H.; Weichel, O.; Bhakdi, S. Potassium inhibited processing of IL-1β in human monocytes. EMBO J. 1995, 14, 1607-1614.
19. Donnelly-Roberts, D. L.; Namovic, M.; Faltynek, C. R.; Jarvis, M. F. Mitogen-activated protein kinase and caspase signaling pathways are required for p2X7 receptor (P2X7R)-induced pore formation in Human THP-1 cells. J. Pharmacol. Exp. Ther. 2004, 308, 1053-1061.
20. 7 receptor -/- mice. Neuroreport 2004, 15, 2387-2391.
21. 7 Receptor-Mediated Release of Excitatory Amino Acids from Astrocytes. J. Neurosci. 2003, 23, 1320-1328.
22. 7 Receptor in the Immune System. Handbook Exp. Pharmacol. 2001, 151, 355-374.
23. 7 receptor: A pivotal role in inflammation and immunomodulation. Drug. Dev. Res. 1998, 45, 207-213.
24. 7 receptors in ischemic and excitotoxic brain injury in vivo. J. Cerebr. Blood Flow Metab. 2003, 23, 381 -384.
25. 7 receptors in neurodegeneration. Eur. J. Pharmacol. 2002, 447, 261-269.
26. (c) Rampe, D.; Wang, L.; Ringheim, G. E. P2X7 receptor modulation of β-amyloid- and LPS-induced cytokine secretion from human macrophages and microglia. J. Neuroimmunol. 2004, 147, 56-61.
27. (d) Wang, X.; Arcuino, G.; Takano, T.; Lin, J.; Peng, W. G.; Wan, P.; Li, P.; Xu, Q.; Liu, Q. S.; Goldman, S. A.; Nedergaard, M. P2X7 receptor inhibition improves recovery after spinal cord injury. Nature Med. 2004, 10, 821-827.
28. (a) Raghavendra, V.; DeLeo, J. A. The role of astrocytes and microglia in persistent pain. Adv. Mol. Cell Biol. 2004, 31, 951-966.
29. (b) Milligan, E. D.; Maier, S. F.; Watkins, L. R. Review: Neuronal-glial interactions in central sensitization. Sem. Pain Med. 2003, 1, 171-183.
30. Woolf, C. J.; Allchorne, A.; Safieh-Garabedien, B.; Poole, S. Cytokines, nerve growth factor and inflammatory hyperalgesia: The contribution of tumor necrosis factor alpha. Br. J. Pharmacol. 1997, 121, 417-424.
31. DeLeo, J. A.; Yezierski, R. P. The role of neuroinflammation and neuroimmune activation in persistent pain. Pain 2001, 90, 1-6.
32. Hanani, M.; Huang, T. Y.; Cherkas, P. S.; Ledda, M.; Pannese, E. Glial cell plasticity in sensory ganglia induced by nerve damage. Neuroscience 2002, 114, 279-283.
33. Costigan, M.; Woolf, C. J. Pain: Molecular mechanisms. J. Pain 2000, 1, 35-44.
34. (a) Labasi, J. M.; Petrushova, N.; Donovan, C.; McCurdy, S.; Lira, P.; Payette, M. M.; Brissette, W.; Wicks, J. R.; Audoly, L.; Gabel, C. A. Absence of the P2X7 receptor alters leukocyte function and attenuates an inflammatory response. J. Immunol. 2002, 168, 6436-6445.
35. (b) Chessell, I. P.; Hatcher, J. P.; Bountra, C.; Michel, A. D.; Hughes, J. P.; Green, P.; Egerton, J.; Murfin, M.; Richardson, J.; Peck, W. L.; Grahames, C. B. A.; Casula, M. A.; Yiangou, Y.; Birch, R.; Anand, P.; Buell, G. N. Pain 2005, 114, 386-396.
36. Dell'Antonio, G.; Quattrini, A.; Cin, E. D.; Fulgenzi, A.; Ferrero, M. E. Relief of inflammatory pain in rats by local use of the selective P2X7 ATP receptor inhibitor, oxidized ATP. Arthritis Rheum. 2002, 46, 3378-3385.
37. Gargett, C. E.; Wiley, J. S. The isoquinoline derivative KN-62 a potent antagonist of the P2Z-receptor of human lymphocytes. Br. J. Pharmacol. 1997, 120, 1483-1490.
38. 7-receptor. Bioorg. Med. Chem. Lett. 2000, 10, 681-684.
39. 7 receptor antagonists: Tyrosyl derivatives synthesized using a sequential parallel synthetic approach. Drug Dev. Res. 2001, 54, 75-87.
40. 7 receptor antagonists: Probing multiple sites for linking and dimerization. Bioconjugate Chem. 2002, 13, 1100-1111.
41. 7 receptor. J. Med. Chem. 2003, 46, 1318-1329.
42. 7 receptor antagonists. Bioorg. Med. Chem. Lett. 2003, 8, 4043-4046.
43. Baxter, A.; Bent, J.; Bowers, K.; Braddock, M.; Brough, S.; Fagura, M.; Lawson, M.; McInally, T.; Mortimer, M.; Robertson, M.; weaver, R.; Webborn, P. Hit-to-lead studies: The discovery of potent adamantane amide P2X7 receptor antagonists. Bioorg. Med. Chem. Lett. 2003, 8, 4047-4050.
44. Perez-Medrano, A.; Donnelly-Roberts, D. L.; Faltynek, C. R.; Honore, P.; Jarvis, M. F.; Peddi, S.; Wang, Y.; Carroll, W. A. Discovery and biological evaluation of novel cyanoguanidine P2X7 antagonists for the treatment of neuropathic pain. J. Med. Chem. Submitted for publication.
45. Huff, B. E.; Staszak, M. A. A new method for the preparation of tetrazoles from nitriles using trimethylsilylazide/trimethylaluminum. Tetrahedron Lett. 1993, 34, 8011-8014.
46. The regiochemistry of the 1,5- and 2,5-substituted products 8a and 8b was determined from the NOE effect observed for the 1,5-isomer between the benzylic protons and the ortho hydrogen on the adjacent group Ar. No NOE effect was observed for the 2,5-isomer.
47. Duncia, J. V.; Pierce, M. E.; Santella, J. B., III. Three synthetic routes to a sterically hindered tetrazole. A new one-step mild conversion of an amide into a tetrazole. J. Org. Chem. 1991, 56, 2395-2400.
48. Panday, N.; Meyyappan, M.; Vasella, A. A comparison of glucose-and glucosamine-related inhibitors: Probing the interaction of the 2-hydroxy group with retaining β-glucosidases. Helv. Chim. Acta 2000, 83, 513-538.
49. Bianchi, B. R.; Lynch, K. J.; Touma, E.; Niforatos, W.; Burgard, E. C.; Alexander, K. M.; Park, H. S.; Yu, H.; Metzger, R.; Kowaluk, E. Pharmacological characterization of recombinant human and rat P2X receptor subtypes. Eur. J. Pharmacol. 1999, 376, 127-138.
50. Jarvis, M. F.; Burgard, E. C.; McGaraughty, S.; Honore P.; Lynch, K.; Brennan, T. J.; Subieta, A.; van Biesen, T.; Cartmell, J.; Bianchi, B.; Niforatos, W.; Kage, K.; Yu, H.; Mikusa, J.; Wismer, C. T.; Zhu, C. Z.; Chu, K.; Lee, C.-H.; Stewart, A. O.; Polakowski, J.; Cox, B. F.; Kowaluk, E.; Williams, M.; Sullivan, J.; Faltynek, C. A-317491, a novel potent and selective nonnucleotide antagonist of P2X3 and P2X2/3 receptors, reduces chronic inflammatory and neuropathic pain in the rat. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 17179-17184.
51. In pharmacokinetic studies, compound 15d was administered at a dose of 10 μmol/kg.